抗有丝分裂药物发现与开发的最新进展。
Recent progress in discovery and development of antimitotic agents.
作者信息
Kiselyov Alex, Balakin Konstantin V, Tkachenko Sergey E, Savchuk Nikolay, Ivachtchenko Alexandre V
机构信息
ChemDiv, Inc. 11558 Sorrento Valley Rd., Ste. 5, San Diego, CA 92121, USA.
出版信息
Anticancer Agents Med Chem. 2007 Mar;7(2):189-208. doi: 10.2174/187152007780058650.
This review highlights structural diversity of antimitotic agents. In particular, we emphasized current antimitotic therapies based on modulation of microtubule dynamics. With several successful anticancer drugs on the market and numerous compounds in clinical developments, tubulin-binding agents remain among the most important categories of anticancer agents. Compounds targeting mitotic kinases and kinesins are also discussed.
本综述重点介绍了抗有丝分裂剂的结构多样性。特别是，我们强调了基于微管动力学调节的当前抗有丝分裂疗法。鉴于市场上有几种成功的抗癌药物以及众多处于临床开发阶段的化合物，微管蛋白结合剂仍然是最重要的抗癌药物类别之一。本文还讨论了靶向有丝分裂激酶和驱动蛋白的化合物。
Zotero 插件